Hemodynamic effects of nitroglycerin combined with diltiazem in patients with coronary artery disease

Insights

The combination of diltiazem and nitroglycerin effectively reduces myocardial oxygen demand in patients with coronary heart disease. This drug combination maintains coronary blood flow without increasing heart rate, suggesting a beneficial therapeutic approach.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Coronary heart disease (CHD) poses significant risks.
  • Understanding hemodynamic effects of cardiovascular drugs is crucial.

Purpose of the Study:

  • To evaluate the combined hemodynamic effects of intravenous diltiazem and nitroglycerin in CHD patients.
  • To compare the combination therapy with monotherapy using either diltiazem or nitroglycerin.

Main Methods:

  • Studied 12 patients with CHD receiving intravenous diltiazem and nitroglycerin combination.
  • Compared results with 7 patients on diltiazem alone and 5 on nitroglycerin alone.
  • Monitored coronary and left ventricular hemodynamics, including blood pressure, heart rate, and cardiac output.

Main Results:

  • The diltiazem-nitroglycerin combination significantly reduced systolic blood pressure (27%) and rate-pressure product (22%).
  • Left ventricular end-diastolic pressure (-36%) and dp/dt (-6.4%) decreased, while coronary flow and cardiac output were maintained.
  • Combination therapy showed greater reduction in myocardial oxygen demand compared to monotherapy, without increasing heart rate.

Conclusions:

  • Diltiazem and nitroglycerin combination therapy offers superior reduction in myocardial oxygen demand than individual drugs.
  • This combination maintains coronary blood flow and cardiac output without adverse increases in heart rate.
  • The diltiazem-nitroglycerin combination shows potential for managing myocardial ischemia and warrants further investigation.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...